Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
3.150
+0.040 (1.29%)
May 5, 2026, 1:55 PM EDT - Market open
Daré Bioscience Revenue
In the year 2025, Daré Bioscience had annual revenue of $1.03M with 10,429.33% growth. Daré Bioscience had revenue of $1.02M in the quarter ending December 31, 2025.
Revenue (ttm)
$1.03M
Revenue Growth
+10,429.33%
P/S Ratio
43.95
Revenue / Employee
$42,925
Employees
24
Market Cap
45.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.03M | 1.02M | 10,429.33% |
| Dec 31, 2024 | 9.78K | -2.80M | -99.65% |
| Dec 31, 2023 | 2.81M | -7.19M | -71.92% |
| Dec 31, 2022 | 10.00M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 80.00K | 74.00K | 1,233.33% |
| Dec 31, 2013 | 6.00K | -619.00K | -99.04% |
| Dec 31, 2012 | 625.00K | 619.00K | 10,316.67% |
| Dec 31, 2011 | 6.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Apollomics | 8.84M |
| CervoMed | 4.01M |
| Pluri | 1.34M |
| Werewolf Therapeutics | 1.14M |
| IGC Pharma | 1.11M |
| Actinium Pharmaceuticals | 90.00K |
DARE News
- 5 weeks ago - Daré Bioscience Earnings Call Transcript: Q4 2025 - Transcripts
- 5 weeks ago - Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - On National Viagra Day, Women Finally Claim Their Turn: - GlobeNewsWire
- 7 weeks ago - Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth - GlobeNewsWire
- 7 weeks ago - Daré Bioscience Participates in Virtual Investor “What This Means” Segment - GlobeNewsWire
- 2 months ago - Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - GlobeNewsWire
- 5 months ago - DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility - GlobeNewsWire
- 6 months ago - Daré Bioscience Earnings Call Transcript: Q3 2025 - Transcripts